AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Scholar Rock (SRRK)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

39.23

1.22 (3.21%)

At close: Feb 20, 2025, 3:59 PM

39.15

-0.22%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	37.46
Market Cap	3.67B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.36
PE Ratio (ttm)	-16.62
Forward PE	n/a
Analyst	Buy

Ask	40.83
Volume	471,917
Avg. Volume (20D)	1,045,000
Open	37.84
Previous Close	38.01
Day's Range	37.32 - 39.46
52-Week Range	6.76 - 46.98
Beta	undefined

About SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical tria...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 25, 2018

Employees 150

Stock Exchange NASDAQ

Ticker Symbol SRRK

Website https://scholarrock.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 7.05% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago

+26.07%

Scholar Rock stock is trading higher after rival B... Unlock content with Pro Subscription

3 months ago

-5.29%

Scholar Rock Holding shares are trading lower after the company reported worse-than-expected Q3 EPS results.

News

1 week ago · businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometa...

3 weeks ago · seekingalpha.com

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 pr...

3 weeks ago · businesswire.com

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis...

1 month ago · benzinga.com

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference.

1 month ago · businesswire.com

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

2 months ago · benzinga.com

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.